BioSpace News Archive

Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., in conjunction with SpineThera, Inc., today announced issuance of U.S. Patent No. 10,350,222 from the United States Patent and Trademark Office.

The Arizona Bioindustry Association (AZBio) today announced the final line up for the fourth annual Arizona Bioscience Week which will begin on September 30, 2019 and conclude on October 4, 2019.

Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in its Phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine.

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/nktr.

Universal Health Services, Inc. announced that Steve Filton, Executive Vice President and Chief Financial Officer will present at the following conferences

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it will be presenting at the Wells Fargo Securities 2019 Healthcare Conference on Thursday, September 5 at the Westin Copley Place in Boston.

The funding, utilized at two leading research institutions in Israel, has supported projects examining DNA and genes JUN and CCNE1 and their correlation to two of the most rampant cancers: Ovarian and Melanoma.

Today, Flatiron Health announced a series of three research publications that developed and evaluated a new approach to capture when a patient’s cancer has worsened based on information contained in the electronic health record (EHR).

Centinel Spine, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that the first implantation took place in an Investigational Device Exemption (IDE) study monitored by the Food and Drug Administration (FDA).

As part of its broader efforts to reign in health care prices that place a tremendous financial burden on families throughout the state, Blue Cross and Blue Shield of Minnesota (Blue Cross) plans to offer insulin coverage to thousands of members with a $0 co-pay at the point-of-sale (pharmacy counter).